Skip to main content
. 2020 Jan 20;80(3):333–341. doi: 10.1016/j.jinf.2019.12.022

Fig. 1.

Fig 1

(A) Three-month overall survival according to the community acquired respiratory virus (CARV) infection period (96% in the prospective cohort vs. 78% in the standard clinical practice cohort, p < 0.0001); (B) Three-month overall survival in recipients with CARV LRTD according to the CARV infection period (94% in the prospective cohort vs. 63% in the standard clinical practice cohort, p < 0.0001).